•Dr. Li's role combines the leadership of corporate R&D strategy, management of the project team, and collaborations with the academic and medical community
•During his research work in Oncology, Immunology, NASH, Diabetes and stem cell biology, Dr. Li focussed on Drug Target Discovery, Mechanism of Action and the technical and commercial evaluation of drug candidates
•He identified several potential drug targets in the TNBC that are resistant to IGF1R inhibitors treatment. He elucidated the interaction of the anti-tropomyosin compound with the Tpm3.1/actin co-polymer
•He also contributed to the literature of Wnt/β-catenin signaling
•Before joining Fontacea, Dr. Li worked at Guangzhou Boji Medical Biotechnological co., Ltd.
•Dr. Li was a Postdoctoral Fellow at University of New South Wales after earned his PhD of Biochemistry from University of Adelaide